




Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Inhibition of human DNA topoisomerase II α by two novel ellipticine derivatives

Kendra R. Vann^a, Yavuz Ergün^d, Sevil Zencir^e, Serkan Oncuoglu^d, Neil Osheroff^{a,b,c,*}, Zeki Topcu^{f,*}^a Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA^b Department of Medicine (Hematology/Oncology), Vanderbilt University School of Medicine, Nashville, TN 37232, USA^c VA Tennessee Valley Healthcare System, Nashville, TN 37212, USA^d Department of Chemistry, Faculty of Science, Dokuz Eylul University, 35160 Izmir, Turkey^e Department of Medical Biology, Faculty of Medicine, Pamukkale University, 20070 Denizli, Turkey^f Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Ege University, 35100 Izmir, Turkey

ARTICLE INFO

Article history:

Received 30 December 2015

Revised 12 February 2016

Accepted 13 February 2016

Available online 15 February 2016

Keywords:

Ellipticine derivatives

DNA topoisomerase II α

Anticancer drugs

Catalytic inhibitor

DNA cleavage

DNA intercalation

ABSTRACT

Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity. Unfortunately, this compound displays a number of adverse properties. Therefore, to investigate new ellipticine-based compounds for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivatives, N-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-N-methyl-5-demethyl ellipticinium iodide (ET-2). As determined by DNA decatenation and cleavage assays, ET-1 and ET-2 act as catalytic inhibitors of human topoisomerase II α and are both more potent than the parent compound. Neither compound impairs the ability of the type II enzyme to bind its DNA substrate. Finally, the potency of ET-1 and ET-2 as catalytic inhibitors of topoisomerase II α appears to be related to their ability to intercalate into the double helix.

© 2016 Elsevier Ltd. All rights reserved.

Type II topoisomerases have been important enzyme targets for medicinal and chemotherapeutic agents since the identification of amsacrine as a topoisomerase II-targeted anticancer drug in 1984.¹ Since that time, an increasing number of naturally occurring and synthetic compounds of pharmacological importance have been reported to exert their activities by interfering with DNA topoisomerase II function.^{2–12} Although lower eukaryotic species encode only one type II topoisomerase, vertebrates encode two closely related isoforms of the enzyme, topoisomerase II α and II β .^{13–18} These enzymes play essential roles in a number of genetic processes, including DNA replication, transcription, and recombination, as well as chromosome segregation.^{13–18} Type II topoisomerases resolve problems associated with the topological constraints of the genetic material (i.e., DNA under- or overwinding, knotting, and tangling) by transiently cleaving both strands of the double helix.^{13–18}

Topoisomerase II-targeted agents act in one of two manners.^{14,15,19–24} Topoisomerase II poisons kill cells by increasing levels of covalent topoisomerase II-cleaved DNA complexes. All of the

clinically relevant topoisomerase II poisons examined to date do so by interfering with the ability of the enzyme to religate cleaved DNA molecules.^{14,15,19,20,22–24} Alternatively, topoisomerase II catalytic inhibitors act by robbing the cell of the essential catalytic functions of the type II enzymes.^{19–21,23} Catalytic inhibitors have been shown to act at a variety of steps of the topoisomerase II catalytic cycle, including DNA cleavage.^{19–21,23}

Ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole), a natural product first isolated from the Australian evergreen tree, is an antineoplastic agent that intercalates into DNA and alters topoisomerase II activity.^{1,25–32} The compound is a mild poison against topoisomerase II from *Drosophila* and *Saccharomyces cerevisiae*.^{29,30} However, most studies report that ellipticine induces little, if any, DNA cleavage mediated by mammalian type II topoisomerases and inhibits enzyme activity at higher concentrations.^{1,27–29} In contrast to the parent compound, several ellipticine derivatives are potent topoisomerase II poisons in mammalian systems and display anticancer activity against human breast cancer and other solid tumors.^{26,32,33} Unfortunately, these compounds induce a number of adverse effects such as dry mouth, weight loss, hemolysis, and renal toxicity. Moreover, the parent compound, ellipticine, displays poor water solubility and target specificity, and drug resistance has been observed upon prolonged administration.^{27,34–36}

* Corresponding authors. Tel.: +1 615 322 4338 (N.O.), +90 232 311 1931 (Z.T.).

E-mail addresses: neil.osheroff@vanderbilt.edu (N. Osheroff), zeki.topcu@ege.edu.tr (Z. Topcu).




Figure 1. Structures and synthetic pathway of the compounds utilized in this study. (Top) The structures of ellipticine, *N*-methyl-5-demethyl ellipticine (ET-1), and 2-methyl-*N*-methyl-5-demethyl ellipticinium iodide (ET-2) are shown. (Bottom) The approach used to synthesize ellipticine derivatives ET-1 and ET-2 is shown. Reagents and conditions: (i) aminoacetaldehyde diethyl acetal, 100 °C, stirred, 4 h. (ii) NaBH₄, methanol, rt, stirred, 2 h. (iii) N(C₂H₅)₃, chloroform, benzenesulfonyl chloride, stirred, rt, 18 h. (iv) 6 N HCl, dioxane, N₂, reflux, 2 h. (v) CH₃I, DMF, stirred, rt, 5 h.




Figure 2. Effects of ellipticine, ET-1, and ET-2 (8–5000 μM) on DNA decatenation catalyzed by human topoisomerase II α . Assays containing intact kDNA in the absence of topoisomerase II α (DNA), or kDNA treated with topoisomerase II α in the absence of ellipticine-based compounds (TII α) or in the presence of compound diluent (TII α + DMSO) are shown as controls. The positions of intact kDNA at the origin (kDNA), decatenated nicked kDNA minicircles, and decatenated supercoiled kDNA minicircles are indicated. Gels are representative of three independent experiments.




Figure 3. Effects of ellipticine, ET-1, and ET-2 on DNA cleavage mediated by human topoisomerase II α . Results for ellipticine (ET; black), ET-1 (ET-1; red), and ET-2 (ET-2; blue) on the generation of enzyme-mediated double-stranded DNA breaks are shown. DNA cleavage levels were calculated relative to control reactions that contained no drug and were set to 100%. Error bars represent standard deviations for at least three independent experiments.

The activities of methylated, hydroxylated, and *N*-alkylated ellipticine analogs have been described previously.^{27,32,33} However, the properties of C5 demethylated compounds have not been analyzed. Thus, in an effort to investigate new ellipticine-based compounds for their potential as topoisomerase II-targeted drugs, we synthesized two novel derivatives, *N*-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-*N*-methyl-5-demethyl ellipticinium iodide (ET-2). Ellipticine derivatives were synthesized via a novel pathway shown in Figure 1. The detailed syntheses and physical and chemical characterizations of ET-1 and ET-2 are described in the accompanying Supplementary Data.

Briefly, ET-1 and ET-2 were generated using a nine-step synthetic pathway with a 12% overall yield (Fig. 1). First, 4,9-dimethyl-9*H*-carbazole-3-carbaldehyde (1) was synthesized in five steps, according to the literature, starting from Hagemann's ester (ethyl-2-methyl-4-oxocyclohex-2-enecarboxylate).^{37,38} We then generated *N*-methyl-5-demethyl ellipticine (ET-1) and 2-methyl-*N*-methyl-5-demethyl ellipticinium iodide (ET-2) in four subsequent steps.³⁹ Aldehyde 1 was treated with aminoacetaldehyde diethylacetal in solvent-free conditions to yield imine 2. The imine was reduced with sodium borohydride to produce amine 3, which




Figure 4. Effects of ET-1 and ET-2 on the binding of negatively supercoiled plasmid by human topoisomerase II α . Results of an electrophoretic mobility shift assay are shown for an enzyme titration carried out in the presence of no compound, 25 μ M ET-1, or 25 μ M ET-2. Enzyme-DNA binding is indicated by the shift of the DNA from the position of negatively supercoiled [(-)SC] plasmid to the origin. Gels are representative of three independent experiments.




Figure 5. Intercalation of ellipticine (ET), ET-1, and ET-2 into relaxed DNA. Results of a topoisomerase I-DNA unwinding assay are shown. Intercalation is indicated by the shift in the position of the plasmid from relaxed (Rel) to negatively supercoiled [(-)SC] DNA. A strong intercalator, ethidium bromide (10 μ M), and a non-intercalator, etoposide (250 μ M), are shown as positive and negative controls, respectively. Assays that contained only the relaxed DNA substrate (DNA) or relaxed DNA and topoisomerase I with no compound (NC) are shown. Gels are representative of three independent experiments.

was treated with benzene sulfonyl chloride to produce sulfonamide 4. Finally, cyclization of ET-1 was achieved by treating sulfonamide 4 with hydrochloric acid in dioxane. ET-2 was obtained by treating ET-1 with iodomethane in dimethyl formamide. Stock solutions of the test compounds (50 mM) were prepared in DMSO. ET-1 and ET-2 both were more soluble than ellipticine.

A number of assays were utilized to compare the effects of ET-1 and ET-2 on human topoisomerase II α with those of the parent compound, ellipticine. First, the effects of the compounds on the overall catalytic activity of the enzyme were monitored using a decatenation assay (Fig. 2). Both ET-1 and ET-2 inhibited the ability of topoisomerase II α to unlink kinetoplast DNA (kDNA) rings and blocked enzyme activity completely at concentrations of 200–1000 μ M. In contrast, ellipticine required a concentration of >5000 μ M to completely inhibit the decatenation activity of the type II enzyme.

Although topoisomerase II poisons act by enhancing levels of DNA cleavage, they still have the capacity to inhibit overall enzyme activity.^{19,40} Therefore, to determine whether ET-1 and ET-2 act specifically as catalytic inhibitors or also have the capacity to act as topoisomerase II poisons, their effects on topoisomerase II α -mediated DNA cleavage were assessed (Fig. 3). As reported previously, ellipticine was a modest inhibitor of DNA cleavage (IC_{50} >200 μ M).^{1,28} Neither ET-1 nor ET-2 enhanced topoisomerase

II α -mediated DNA cleavage and both inhibited the DNA scission activity of the enzyme to a much greater extent than ellipticine. The IC_{50} for the two compounds were \sim 40 and 5 μ M, respectively.

Catalytic inhibitors can block enzyme activity at a number of different steps of the topoisomerase II catalytic cycle.^{19–21} Compounds that inhibit the enzyme have been shown to act by blocking DNA binding, cleavage, or strand passage, or by interfering with ATP binding/hydrolysis. Because ET-1 and ET-2 inhibited DNA cleavage, we examined the effects of these compounds on topoisomerase II α -DNA binding to determine whether the compounds are specific for DNA cleavage or act at a prior step in the catalytic cycle. ET-1 and ET-2 were used at 25 μ M for this experiment, because DNA cleavage was inhibited substantially (\sim 40% and 80% inhibition, respectively) at this concentration. Enzyme-DNA binding was monitored using an electrophoretic mobility shift assay (Fig. 4). Neither ET-1 nor ET-2 displayed any ability to inhibit topoisomerase II α -DNA binding at the concentration employed. In fact, ET-2 appeared to enhance enzyme-DNA binding by \sim 50%. Thus, we conclude that ET-1 and ET-2 inhibit DNA cleavage without altering the ability of topoisomerase II α to bind its DNA substrate.

The ability of ellipticine to intercalate into DNA appears to play an important role in its antineoplastic activity.³⁶ Because ET-1 and ET-2 are more potent inhibitors of human topoisomerase II α than ellipticine, a topoisomerase I-DNA unwinding assay was utilized to compare the ability of these compounds to intercalate into relaxed plasmid DNA (Fig. 5). As determined by the shift in the plasmid from relaxed to negatively supercoiled DNA, all of the compounds intercalated into DNA. Similar to the inhibition of DNA cleavage observed with the compounds (see Fig. 3), the relative potency of intercalation was ET-2 > ET-1 \gg ellipticine. This finding suggests that the ability of the ellipticine derivatives to inhibit the activity of topoisomerase II α is related to their ability to intercalate into the double helix.

There is a need for the development of new anticancer drugs. Given the demonstrated antineoplastic activity of ellipticine, derivatives of this compound have the potential to display greater activity against cells or enzyme targets.^{11,32,41} Results of the present study indicate that ET-1 and ET-2 are catalytic inhibitors of human topoisomerase II α . Furthermore, both are more potent than ellipticine, and the activity of ET-1 and ET-2 toward the type II enzyme appears to be related to their enhanced ability to intercalate into DNA.

Acknowledgements

The authors declare no competing financial interests. This research was supported by grant GM033944 (N.O.) from the National Institutes of Health and grant 1152349 (Z.T.) from the Turkish Scientific and Technical Research Assembly. K.R.V. was a trainee under National Institutes of Health grants R25-GM062459

and T32-GM08320 and was supported in part by a Research Supplement to Grant GM033944 to Promote Diversity in Health-Related Research. We are grateful to Rachel E. Ashley, Lorena Infante Lara, and Elizabeth G. Gibson for critical reading of the manuscript.

Supplementary data

Supplementary data (experimental details for the synthesis and characterization of ET-1 and ET-2, as well as sources of materials and methods for biochemical assays) associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2016.02.034>. These data include MOL files and InChIKeys of the most important compounds described in this article.

References and notes

1. Tewey, K. M.; Chen, G. L.; Nelson, E. M.; Liu, L. F. *J. Biol. Chem.* **1984**, 259, 9182.
2. Austin, C. A.; Patel, S.; Ono, K.; Nakane, H.; Fisher, L. M. *Biochem. J.* **1992**, 282, 883.
3. Wang, H.; Mao, Y.; Chen, A. Y.; Zhou, N.; LaVoie, E. J.; Liu, L. F. *Biochemistry* **2001**, 40, 3316.
4. Bandele, O. J.; Clawson, S. J.; Osheroff, N. *Chem. Res. Toxicol.* **2008**, 21, 1253.
5. Bandele, O. J.; Osheroff, N. *Chem. Res. Toxicol.* **2008**, 21, 936.
6. Ketron, A. C.; Gordon, O. N.; Schneider, C.; Osheroff, N. *Biochemistry* **2013**, 52, 221.
7. Senarisoy, M.; Canturk, P.; Zencir, S.; Baran, Y.; Topcu, Z. *Cell Biochem. Biophys.* **2013**, 66, 199.
8. Ashley, R. E.; Osheroff, N. *Chem. Res. Toxicol.* **2014**, 27, 787.
9. Ketron, A.; Osheroff, N. *Phytochem. Rev.* **2014**, 13, 19.
10. Zupko, I.; Molnar, J.; Rethy, B.; Minorics, R.; Frank, E.; Wolfling, J.; Molnar, J.; Ocsosvzski, I.; Topcu, Z.; Bito, T.; Puskas, L. G. *Molecules* **2014**, 19, 2061.
11. Stiborova, M.; Frei, E. *Curr. Med. Chem.* **2014**, 21, 575.
12. Vann, K. R.; Sedgeman, C. A.; Gopas, J.; Golan-Goldhirsh, A.; Osheroff, N. *Biochemistry* **2015**, 54, 4531.
13. Deweese, J. E.; Osheroff, M. A.; Osheroff, N. *Biochem. Mol. Biol. Educ.* **2008**, 37, 2.
14. Deweese, J. E.; Osheroff, N. *Nucleic Acids Res.* **2009**, 37, 738.
15. Nitiss, J. L. *Nat. Rev. Cancer* **2009**, 9, 327.
16. Liu, Z.; Deibler, R. W.; Chan, H. S.; Zechiedrich, L. *Nucleic Acids Res.* **2009**, 37, 661.
17. Vos, S. M.; Tretter, E. M.; Schmidt, B. H.; Berger, J. M. *Nat. Rev. Mol. Cell. Biol.* **2011**, 12, 827.
18. Chen, S. H.; Chan, N.-L.; Hsieh, T.-S. *Ann. Rev. Biochem.* **2013**, 82, 139.
19. Fortune, J. M.; Osheroff, N. *Prog. Nucleic Acid Res. Mol. Biol.* **2000**, 64, 221.
20. Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. *Pharmacol. Ther.* **2003**, 99, 167.
21. Chene, P.; Rudloff, J.; Schoepfer, J.; Furet, P.; Meier, P.; Qian, Z.; Schlaeppli, J. M.; Schmitz, R.; Radimerski, T. *BMC Chem. Biol.* **2009**, 9, 1.
22. Pommier, Y.; Leo, E.; Zhang, H.; Marchand, C. *Chem. Biol.* **2010**, 17, 421.
23. Pogorelcnik, B.; Perdih, A.; Solmajer, T. *Curr. Pharm. Des.* **2013**, 19, 2474.
24. Pommier, Y. *ACS Chem. Biol.* **2013**, 8, 82.
25. Goodwin, S.; Smith, A. F.; Horning, E. C. *J. Am. Chem. Soc.* **1959**, 81, 1903.
26. Auclair, C. *Arch. Biochem. Biophys.* **1987**, 259, 1.
27. Monnot, M.; Mauffret, O.; Simon, V.; Lescot, E.; Psaume, B.; Saucier, J. M.; Charra, M.; Belehradek, J., Jr.; Femandjian, S. *J. Biol. Chem.* **1991**, 266, 1820.
28. Fosse, P.; Rene, B.; Charra, M.; Paoletti, C.; Saucier, J. M. *Mol. Pharmacol.* **1992**, 42, 590.
29. Froelich-Ammon, S. J.; Patchan, M. W.; Osheroff, N.; Thompson, R. B. *J. Biol. Chem.* **1995**, 270, 14998.
30. Cline, S. D.; Macdonald, T. L.; Osheroff, N. *Biochemistry* **1997**, 36, 13095.
31. Garbett, N. C.; Graves, D. E. *Curr. Med. Chem. Anticancer Agents* **2004**, 4, 149.
32. Kizek, R.; Adam, V.; Hrabeta, J.; Eckschlager, T.; Smutny, S.; Burda, J. V.; Frei, E.; Stiborova, M. *Pharmacol. Ther.* **2012**, 133, 26.
33. Multon, E.; Riou, J.-F.; LeFevre, D.; Ahomadegbe, J.-C.; Riou, G. *Biochem. Pharm.* **1989**, 38, 2077.
34. Rouesse, J.; Spielmann, M.; Turpin, F.; Le Chevalier, T.; Azab, M.; Mondesir, J. M. *Eur. J. Cancer* **1993**, 29A, 856.
35. Kattan, J.; Durand, M.; Droz, J. P.; Mahjoubi, M.; Marino, J. P.; Azab, M. *Am. J. Clin. Oncol.* **1994**, 17, 242.
36. Paoletti, C.; Le Pecq, J. B.; Dat-Xuong, N.; Juret, P.; Garnier, H.; Amiel, J. L.; Rouesse, J. *Recent Res. Cancer Res.* **1980**, 74, 107.
37. Karmakar, S.; Dixit, R.; Nath, A.; Kumar, S.; Karmakar, S. *Indian J. Pharmacol.* **2012**, 44, 131.
38. Ergün, Y.; Patir, S.; Okay, G. J. *J. Heterocycl. Chem.* **1998**, 35, 1445.
39. Yokoyama, Y.; Okuyama, N.; Iwadate, S.; Momoi, T.; Murakami, Y. *J. Chem. Soc. Perkins Trans. 1* **1990**, 1319.
40. McClendon, A. K.; Osheroff, N. *Mutat. Res.* **2007**, 623, 83.
41. Russell, E. G.; O'Sullivan, E. C.; Miller, C. M.; Stanicka, J.; McCarthy, F. O.; Cotter, T. G. *Invest. New Drugs* **2014**, 32, 1113.